FOLH1 and prostate carcinoma: ProstaScint ([111In]In-capromab-pentitide) was the first FDA-approved mAb-based imaging, employing a mAb against PSMA (7E11) to detect occult pelvic lymph node metastases and recurrence of prostate cancer (211, 212).